Sekine Ikuo, Sumi Minako, Ito Yoshinori, Nokihara Hiroshi, Yamamoto Noboru, Kunitoh Hideo, Ohe Yuichiro, Kodama Tetsuro, Saijo Nagahiro, Tamura Tomohide
Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Radiother Oncol. 2006 Jul;80(1):93-7. doi: 10.1016/j.radonc.2006.06.007. Epub 2006 Jul 3.
To disclose characteristics of lung cancer patients developing radiation-induced lung injury treated with or without corticosteroid therapy.
Radiographic changes, symptoms, history of corticosteroid prescription, and clinical course after 50-70 Gy of thoracic radiotherapy were retrospectively evaluated in 385 lung cancer patients.
Radiation-induced lung injury was stable without corticosteroid in 307 patients (Group 1), stable with corticosteroid in 64 patients (Group 2), and progressive to death despite corticosteroid in 14 patients (Group 3). Fever and dyspnea were noted in 11%, 50% and 86% (p<0.001), and in 13%, 44% and 57% (p<0.001) patients in Groups 1-3, respectively. Median weeks between the end of radiotherapy and the first radiographic change were 9.9, 6.7 and 2.4 for Groups 1-3, respectively (p<0.001). The initial prednisolone equivalent dose was 30-40 mg daily in 52 (67%) patients. A total of 16 (4.2%) patients died of radiation pneumonitis or steroid complication with a median survival of 45 (range, 8-107) days.
Development of fever and dyspnea, and short interval between the end of radiotherapy and the first radiographic change were associated with fatal radiation-induced lung injury. Prednisolone 30-40 mg daily was selected for the treatment in many patients.
揭示接受或未接受皮质类固醇治疗的肺癌患者发生放射性肺损伤的特征。
对385例肺癌患者进行回顾性评估,这些患者接受了50 - 70 Gy的胸部放疗,评估内容包括影像学变化、症状、皮质类固醇处方史及临床病程。
307例患者(第1组)未使用皮质类固醇时放射性肺损伤稳定,64例患者(第2组)使用皮质类固醇时稳定,14例患者(第3组)即使使用皮质类固醇仍病情进展至死亡。第1 - 3组患者中,分别有11%、50%和86%(p<0.001)出现发热,13%、44%和57%(p<0.001)出现呼吸困难。第1 - 3组放疗结束至首次影像学变化的中位周数分别为9.9、6.7和2.4(p<0.001)。52例(67%)患者初始泼尼松龙等效剂量为每日30 - 40 mg。共有16例(4.2%)患者死于放射性肺炎或类固醇并发症,中位生存期为45天(范围8 - 107天)。
发热和呼吸困难的出现以及放疗结束至首次影像学变化的间隔时间短与致命性放射性肺损伤相关。许多患者选择每日30 - 40 mg泼尼松龙进行治疗。